Published in Vaccine Weekly, June 16th, 2004
According to a study from the United States, "Wild-type mice immunized with MART-1 melanoma antigen-engineered dendritic cells (DC) generate strong antigen-specific immunity that has an absolute requirement for both CD8+ and CD4+ T cells. DC administration to CD8alpha knockout mice displayed unexpectedly enhanced levels of protection to tumor challenge despite this deficiency in CD8+ T cells and the inability to mount MHC class I-restricted immune responses."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly